Printer Friendly

IVAX CORPORATION ANNOUNCES THE APPROVAL OF ITS ABBREVIATED NEW DRUG APPLICATION FOR TOLMETIN

 IVAX CORPORATION ANNOUNCES THE APPROVAL OF ITS
 ABBREVIATED NEW DRUG APPLICATION FOR TOLMETIN
 MIAMI, Jan. 31 /PRNewswire/ -- IVAX Corporation (AMEX: IVX) announced today that its wholly owned subsidiary Baker Cummins Pharmaceuticals, Inc. received the approval from the United States Food and Drug Administration of its Abbreviated New Drug Application for the off-patent pharmaceutical product tolmetin capsule, 400 mg. Tolmetin is a nonsteroidal anti-inflammatory drug used for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and for the treatment of juvenile rheumatoid arthritis and is currently sold under the brand name Tolectin(R) DS by McNeil Pharmaceutical, a division of Johnson & Johnson. Tolectin(R) is a registered trademark of Johnson & Johnson.
 Charles Hsiao, Ph.D., the president of Baker Cummins Pharmaceuticals, Inc., said, "The approval of tolmetin is a significant milestone for the Baker Cummins Pharmaceuticals since it is the first pharmaceutical product developed by the company to be approved by the FDA. The company is actively engaged in the research and development of a number of pharmaceutical products, and we hope this will be the first of many approvals."
 IVAX Corporation is a holding company with subsidiaries involved in specialty chemicals, pharmaceuticals and medical diagnostics. IVAX' principal subsidiaries include Baker Cummins Pharmaceuticals, Inc., a developer and marketer of unique brand name pharmaceuticals; Norton Healthcare Limited, a leading manufacturer and marketer of off-patent pharmaceuticals in the United Kingdom, Ireland and other countries; Goldline Laboratories, Inc., a national marketer of off-patent prescription and over the counter pharmaceuticals in the United States; Best Generics, Inc., a national distributor of off-patent pharmaceuticals in the United States; Baker Cummins Dermatologicals, Inc., a dermatological products company; Diamedix Corporation, a medical diagnostics company; Delta Biologicals S.r.l., a marketer of medical diagnostic tests and instruments in Italy; and IVAX Industries, Inc., a chemical specialties business.
 -0- 1/31/92
 /CONTACT: Richard C. Pfenniger Jr., senior vice president of legal affairs of IVAX Corporation, 305-590-2309/
 (IVX) CO: IVAX Corporation ST: Florida IN: MTC SU:


AW-SS -- FL003 -- 5538 01/31/92 10:44 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 31, 1992
Words:339
Previous Article:GLAXO'S ZOFRAN OFFERS CANCER PATIENTS BETTER QUALITY OF LIFE DURING CHEMOTHERAPY
Next Article:PURCHASING MANAGERS REPORT DEPRESSED ENTRY INTO 1992
Topics:


Related Articles
IVAX CORPORATION ANNOUNCES THE APPROVAL OF ITS ABBREVIATED NEW DRUG APPLICATION FOR VERAPAMIL
IVAX CORPORATION ANNOUNCES THE APPROVAL OF ITS ABBREVIATED NEW DRUG APPLICATION FOR VERAPAMIL
IVAX COMMENCES DISTRIBUTION OF VERAPAMIL
IVAX CORPORATION ANNOUNCES GENERIC DRUG APPROVAL
IVAX CORPORATION ANNOUNCES GENERIC DRUG APPROVAL
IVAX TO COMMENCE SELLING GENERIC DURICEF(R) IN U.S.; FDA APPROVES IVAX' AADA SUPPLEMENT FOR CEFADROXIL
IVAX CORPORATION ANNOUNCES GENERIC DRUG APPROVAL; FDA APPROVES ANDA FOR TOLMETIN SODIUM
IVAX Corporation Announces Generic Drug Approval
IVAX Receives Final Approval To Market Generic Terfenadine
IVAX Announces Generic Drug Approval For Etodolac.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters